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Abstract 
Cases of acute disseminated encephalomyelitis (ADEM) and its hyperacute form, acute hemorrhagic leu-
koencephalitis (AHLE), have been reported in coronavirus disease 2019 (COVID-19) patients as rare, but most 
severe neurological complications. However, histopathologic evaluations of ADEM/AHLE pathology in COVID pa-
tients are extremely limited, so far having only been reported in a few adult autopsy cases. Here we compare the 
findings with an ADEM-like pathology in a pediatric patient taken through a biopsy procedure. Understanding 
the neuropathology may shed informative light on the autoimmune process affecting COVID-19 patients and 
provide critical information to guide the clinical management. 
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Numerous evidence has confirmed that coro-
navirus disease 2019 (COVID-19), caused by severe 
acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) [1], affects the nervous system [2]. Most of 
the associated neurological dysfunctions are mild 
symptoms such as anosmia and dysgeusia [3] while 
severe debilitating neurological disorders such as 
stroke and meningoencephalitis are less frequent [4, 
5]. These manifestations are likely caused by SARS-
CoV-2 entering brain through direct infection of ol-
factory neuroepithelium [6], or transmitted by circu-
lating lymphocytes and monocytes that are able to 
cross the blood-brain barrier [7]. Within the brain 
and spinal cord, various cell types including endo-
thelial cells, vascular pericytes and smooth muscle, 
neurons and glia all express angiotensin converting 
enzyme 2 (ACE2) receptor [8, 9], the primary recep-
tor for SARS-CoV-2 spike protein [10]. It is true that 
SARS-CoV-2 could be detected in olfactory epithe-
lium [11], brain and cranial nerves by RT-PCR [12, 
13], immunohistochemistry (IHC) [14], in situ hybrid-
ization (ISH) [11] and electron microscopy [15]. In 
addition, neuropathological findings such as lep-
tomeningeal and parenchymal lymphocytic inflam-
mation, microglial nodules and neuronophagy are 
compatible with a diagnosis of viral meningoen-
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cephalitis [12, 16]. Nevertheless, neither viral inclu-
sions nor cytopathic changes have been observed on 
hematoxylin and eosin (H&E) stained slides. Further-
more, in the few studies that have reported evi-
dence of viral RNA or protein in the cranial nerves or 
brainstem, the degree and distribution of neuro-
pathologic changes have shown no correlation with 
the amount of virus in a given area of pathology, 
suggesting that the pathology is rather secondary to 
the systemic effects of viral infection. Indeed, con-
vincing evidence has elucidated that systemic hyper-
coagulability plays an important role in COVID-19 re-
lated stroke process, as SARS-CoV-2 could induce cy-
tokine storm and endotheliopathy [17, 18], which in 
turn lead to the histologic findings of microthrombi, 
hemorrhages and infarcts [19, 20]. 
In contrast, there is still considerable debate 
over whether parainfectious, autoimmune medi-
ated process such as acute disseminated encephalo-
myelitis (ADEM), or its hyperacute form, acute hem-
orrhagic leukoencephalopathy (AHLE), can truly be 
attributed to COVID-19. One reason for this contro-
versy is the lack of neuropathological descriptions of 
ADEM and AHLE despite that a handful clinical and 
imaging case studies of COVID-19 patients have sug-
gested lesions characteristic of ADEM or AHLE [21-
31]. So far, there are only few case reports with neu-
ropathological features of ADEM and AHLE in adult 
patients who died from complications of COVID-19 
[32-34]. Another reason for the controversy, as will 
be discussed further below, is whether the observed 
ADEM- or AHLE-like pathology is truly due to a pri-
mary demyelinating process or merely a secondary 
white matter injury of a comorbid vascular disease 
or a combination. R. Ross Reichard et al. reported 
the neuropathological findings of a 71-year-old pa-
tient who died from complications of COVID-19 [32]. 
Hemorrhagic white matter lesions were present 
throughout the cerebral hemispheres. Luxol fast 
blue/ periodic acid–Schiff (LFB/PAS) identified loss 
of myelin, PAS-positive macrophages, and frag-
mented axonal processes within these lesions. It has 
features of AHLE, although necrotic blood vessels 
and perivascular inflammation were not identified 
within the hemorrhagic lesions. A second distinct 
pathology identified was characterized by small sub-
cortical white matter pallor with a variable perivenu-
lar distribution, resembling an ADEM-like histologi-
cal appearance. Notably, prominent acute axonal in-
jury was present in the regions of myelin loss, which 
is not characteristic of classic ADEM [32]. Jamie M. 
Walker et al. presented two cases of fatal COVID-19 
with severe neurologic sequalae [33]. One was a 51-
year-old woman with an irregular pattern of demy-
elination centered primarily around veins and ven-
ules. Both perivascular CD3+ T-lymphocytes as well 
as frequent perivascular and parenchymal CD68+ 
histiocytes and activated microglial cells were pre-
sent, consistent with a diagnosis of ADEM. Another 
autopsy examination of a 64-year-old demonstrated 
myelin pallor, perivascular CD3+ T-lymphocytes, ax-
onal spheroids, as well as numerous ring- and ball-
hemorrhages throughout the white matter with 
central blood vessels showing fibrinoid necrosis, 
most consistent with a diagnosis of AHLE. It should 
be noted that in all three aforementioned cases, 
global hypoxic-ischemic injury was present, in addi-
tion to microscopic cortical infarcts in the first case 
[32] and large areas of cerebral intraparenchymal 
hemorrhages in the third case [33]. Thus, the neuro-
pathological lesions should be interpreted with cau-
tion and the possibility of a cerebrovascular origin 
with secondary demyelinating pathology should be 
considered. 
ADEM and AHLE usually affects children and 
young adults after an infection or vaccination [35]. 
However there are very few reported cases of ADEM 
in pediatric population with SARS-CoV-2 infection 
based on clinical features and MRI findings [25, 36, 
37]. This is consistent with the differing clinical 
presentations of COVID-19 in children and adult pa-
tients. Recently, we have examined a brain biopsy 
taken from an 8-year-old girl who was admitted with 
new-onset seizures. On hospital day 2, COVID-19 
spike IgG antibody testing was positive. Brain MRI 
demonstrated extensive T2 hyperintensity centered 
at bilateral basal ganglia, extending to the frontal 
white matter, external and internal capsules, corpus 
callosum, thalami, insula, as well as the cerebellar 
hemispheres, brainstem and the spinal cord. Inter-
val MRI imaging demonstrated persistent diffusion 
restriction in the affected white matter throughout 
much of the central white matter tracts, cerebral pe-
duncles, corticospinal tracts and cerebellar white 
matter, suggesting ongoing demyelination, but no 
evidence to suggest hemorrhages. Three weeks 
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Figure 1. Neuropathological findings of a brain biopsy from a child post SARS-CoV-2 infection. A. H&E section of white matter pallor, 
reactive astrogliosis and perivascular lymphocytic infiltrates around small veins and venules. B. LFB stain demonstrates the perivascular 
myelin loss within the subcortical white matter lesion. C. Neurofilament immunostain shows preservation of most axons in the region of 
myelin loss. D. APP immunostain identifies axonal swellings adjacent to the perivascular areas. E. Perivascular lymphocytes are predomi-
nantly CD3-positive T cell. F. CD68 immunostain confirms both perivascular and diffuse distributions of macrophages within the area of 
white matter pallor. Scale bar, 100 μm in A-E. 
 
 
later, there was vacuolating necrosis in bilateral ba-
sal ganglia. Ventriculoperitoneal shunt placement 
and stereotactic brain biopsy were performed on 
hospital day 48. Neuropathological examination of 
the brain biopsy tissue revealed subcortical white 
matter pallor with perivascular lymphocytic infil-
trates centered primarily around venules (Figure 
1A). Immunohistochemical staining for SARS-CoV-2 
spike protein was negative. No microglial nodules or 
evidence of neuronophagia was present. Demye-
lination was confirmed by LFB stain (Figure 1B) 
whereas axons were relatively preserved as shown 
by neurofilament immunostain (Figure 1C). Interest-
ingly, APP immunostain highlighted damaged, swol-
len axons in areas surrounding the vessels, a pattern 
seen in adult patient as well (Figure 1D). The lym-
phocytes were composed predominantly of CD3-
positive T cells (Figure 1E) whereas CD68 stain high-
lighted numerous perivascular macrophages and 
the diffuse distribution of activated microglia (Figure 
1F). 
In this case, the absence of confounding con-
comitant cerebrovascular lesions makes the patho-
logical interpretation relatively straightforward. 
These ADEM/AHLE cases represent rare, but the 
most severe end of the COVID-19 neuropathologic 
spectrum. Consequently, ADEM/AHLE should be a 
consideration during evaluation of patients, espe-
cially children with encephalopathy, seizures and/or 
focal neurologic deficits after recovering from 
COVID-19. Another intriguing development in this 
pediatric patient is the later MRI findings of bilateral 
basal ganglia necrosis, suggestive an even rarer en-
tity, acute necrotizing encephalopathy (ANE), also 
referred as acute necrotizing encephalopathy of 
childhood. ANE is characterized by multiple, sym-
metrical lesions in the thalami, striatum, cerebral 
white matter, and brain stem [38]. Despite its asso-
ciation with viral infection, ANE is not considered an 
inflammatory encephalitis in comparison to ADEM 
and AHLE. In fact, it has been suggested that an in-
tense surge of cytokines causes damage to the 
blood-brain barrier with necrosis as a secondary ef-
fect [39]. Given SARS-CoV-2 is a cytokine storm trig-
ger, it is not surprising to observe ANE as a probable 
association of COVID-19 [40, 41]. It would be im-
portant to understand whether these parainfectious 
demyelinating diseases reflect distinct pathological 
processes or a continuum of a single disease.  
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